Anandamide (AEA)



Anandamide (AEA)
Anandamide is an endogenous cannabinoid neurotransmitter. The name is taken from the Sanskrit word ananda, which means "bliss, delight", and amide. It is synthesized from N-arachidonoyl phosphatidylethanolamine by multiple pathways. It is degraded primarily by the fatty acid amide hydrolase (FAAH) enzyme, which converts anandamide into ethanolamine and arachidonic acid. As such, inhibitors of FAAH lead to elevated anandamide levels and are being pursued for therapeutic use. Anandamide's effects can be either central, in the brain, or peripheral, in other parts of the body. These distinct effects are mediated primarily by CB1 cannabinoid receptors in the central nervous system, and CB2 cannabinoid receptors in the periphery. The latter are mainly involved in functions of the immune system. Anandamide is also important for implantation of the early stage embryo in its blastocyst form into the uterus.

Organism species: Pan-species (General)

Proteins CPO440Ge11 BSA Conjugated Anandamide (AEA) Immunogen; SDS-PAGE; WB.
CPO440Ge21 OVA Conjugated Anandamide (AEA) Immunogen; SDS-PAGE; WB.
Antibodies PAO440Ge01 Polyclonal Antibody to Anandamide (AEA) WB; IHC; ICC; IP.
Assay Kits CEO440Ge ELISA Kit for Anandamide (AEA) Enzyme-linked immunosorbent assay for Antigen Detection.